The present invention is directed to compounds and methods for the treatment
of metastatic disease. The compounds of this invention have specificity for EphA2,
an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells.
The compounds used in accordance with this invention may be provided in a pharmaceutical
composition for treatment of metastatic disease.
